119. Substance Abuse and Mental Health Services Administration: SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA) 13–4742. Rockville M, 2013, Substance Abuse and Mental Health Services Administration. In. 120. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12 Suppl 2:S26-35. 121. Porucznik CA, Johnson EM, Sauer B, Crook J, Rolfs RT. Studying adverse events related to prescription opioids: the Utah experience. Pain Med. 2011;12 Suppl 2:S16-25. 122. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98. 123. Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med. 2017. 124. Agency for Healthcare Quality and Research (AHRQ). Choosing nonopioid analgesics for osteoarthritis: clinician summary guide. J Pain Palliat Care Pharmacother. 2009;23(4):433- 457. 125. Zedler B, Xie L, Wang L, et al. Development of a risk index for serious prescription opioid- induced respiratory depression or overdose in Veterans’ Health Administration patients. Pain Med. 2015;16(8):1566-1579. 126. Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a Screening Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health Plan Claims Database. Pain Med. 2018;19(1):68-78. 127. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat. 2007;32(2):189-198. 128. Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res. 2007;31(2):185- 199. 129. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155-1160. 130. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442. 131. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372. 132. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681. 133. Holmes CP, Gatchel RJ, Adams LL, et al. An opioid screening instrument: long-term evaluation of the utility of the Pain Medication Questionnaire. Pain Pract. 2006;6(2):74-88.
134. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1- 2):144-156. 135. Compton PA, Wu SM, Schieffer B, Pham Q, Naliboff BD. Introduction of a Self-report Version of the Prescription Drug Use Questionnaire and Relationship to Medication Agreement Non-Compliance. J Pain Symptom Manage. 2008;36(4):383-395. 136. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94(3):135-140. 137. Argoff CE, Alford DP, Fudin J, et al. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med. 2018;19(1):97-117. 138. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. Can Med Assoc J. 2017;189(18):E659. 139. U.S. Department of Justice, National Drug Intelligence Center. National drug threat assessment summary 2014: Controlled prescription drugs. https:// info.publicintelligence. net/DEA-DrugThreats-2014.pdf. Published November 2014. Accessed 3-23-18. 140. Dowell D. 2019 CDC opioid guideline clarification letter to ASCO, ASH, NCCN. asco.org. www.asco. org/sites/new-www.asco.org/files/content-files/ advocacy-and-policy/documents/2019-CDC- Opioid-Guideline-Clarification-Letter-to-ASCO- ASH-NCCN.pdf Published February 28, 2019. Accessed April 30, 2021. 141. Federation of State Medical Boards (FSMB). Guidelines for the chronic use of opioid analgesics. https://www.fsmb.org/opioids/. Published April 2017. Accessed January 26, 2021. 142. Argoff CE, Silvershein DI. A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs. Mayo Clin Proc. 2009;84(7):602-612. 143. U.S. Food and Drug Administration. New safety measures announced for extended-release and long-acting opioids. http://www.fda.gov/ Drugs/DrugSafety/InformationbyDrugClass/ ucm363722.htm. Accessed 3-1-18. Published September 20, 2015. Accessed. 144. Covington EC, Argoff CE, Ballantyne JC, et al. Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations. Mayo Clin Proc. 2020;95(10):2155-2171. 145. Centers for Disease Control and Prevention. Calculating Total Daily Dose of Opioids for Safer Dosage. https://www.cdc.gov/drugoverdose/pdf/ calculating_total_daily_dose-a.pdf. Accessed 7-18-19. 146. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439. 147. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425.
148. Centers for Disease Control and Prevention. Preventing an opioid overdose. https://www. cdc.gov/drugoverdose/.../Preventing-an-Opioid- Overdose-Tip-Card-a.pdf. Accessed 3-20-18. 149. Passik SD, Kirsh KL, Whitcomb L, et al. Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool. J Opioid Manag. 2005;1(5):257-266. 150. Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345- 359. 151. Saunders JB. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry. 2017;30(4):227-237. 152. Centers for Disease Control and Prevention. Pocket Guide: Tapering Opioids for Chronic Pain. https://www.cdc.gov/drugoverdose/prescribing/ clinical-tools.html. Accessed December 17, 2019. SUBOXONE (buprenorphine and naloxone). https://www. suboxone.com/pdfs/prescribing-information.pdf. Accessed December 17, 2019. 154. Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav. 2016;61:99-103. 155. Morasco B, Nugent, S. Management of Chronic Pain with Medical Marijuana: Clinical Correlates and an Update on the Evidence: Oregon Health & Science University. https://pdfs.semanticscholar. org/presentatio n/57df/1d81edbe674117 6552a06300e0db8512d60a.pdf. Accessed 4-10-18. 156. Savage SR, Romero-Sandoval A, Schatman 153. Prescribing Information: M, et al. Cannabis in Pain Treatment: Clinical and Research Considerations. J Pain. 2016;17(6):654-668. 157. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test- Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1-2):137-143. 158. Lee CM, Neighbors C, Hendershot CS, Grossbard JR. Development and preliminary validation of a comprehensive marijuana motives questionnaire. J Stud Alcohol Drugs. 2009;70(2):279-287. 159. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.
70
Powered by FlippingBook